UBS maintains Advance Auto Parts stock rating, citing transformation progress

Advance Auto Parts (AAP) reiterated confidence in its multi-year transformation plan, aiming for a 7% operating margin by 2027 through internal efficiencies, despite acknowledging nonlinear progress and tariff challenges. The company reported Q2 2025 adjusted EPS of $0.69, beating estimates, but revenue of $2 billion was down 8% year-over-year, and 13 analysts recently lowered future earnings expectations. UBS maintained a Neutral rating and $65 price target, indicating that while successful execution could drive significant outperformance, the market is unlikely to reward the stock until consistent progress is demonstrated, leading to a balanced risk-reward profile at current levels amid mixed analyst sentiment.

Analysis

Advance Auto Parts (AAP) is in the early stages of a significant multi-year transformation, with management expressing confidence in achieving a 7% operating margin by 2027 through internal controls such as sourcing and supply chain efficiencies. However, this optimism is tempered by the company's own admission of a likely nonlinear path to recovery and external headwinds from tariffs. Recent Q2 2025 results highlight this dichotomy: while adjusted diluted EPS of $0.69 represented a 30.19% beat over forecasts, revenue of $2 billion was down 8% year-over-year, indicating ongoing market-level challenges. Analyst sentiment reflects this uncertainty. Despite some positive notes on business stabilization and professional segment growth from firms like Truist and Evercore ISI, a broader bearish signal comes from 13 analysts revising future earnings expectations downward. UBS's Neutral rating and $65 price target encapsulate the current market view, suggesting a balanced risk-reward profile where significant stock outperformance is contingent on successful execution, but the market will likely withhold credit until consistent progress is demonstrated.

Key Decisions for Investors

• Investors should treat AAP as a 'show-me' story, monitoring for tangible evidence of its turnaround, such as sequential revenue stabilization and margin improvement, as the market is unlikely to re-rate the stock on management guidance alone.
• The significant Q2 EPS beat should be weighed against the 8% year-over-year revenue decline and downward earnings revisions from 13 analysts, suggesting underlying operational and market pressures persist despite some cost control.
• Given the mixed analyst price targets and the balanced risk-reward profile cited by UBS, a neutral stance may be warranted until the company demonstrates more consistent progress in its three-year transformation plan.